Rousselot teases Nextida collagen targeting glucose control

The firm revealed it would soon launch a range called Nextida, an extensive library of specific compositions that could trigger new modes of actions for specific health benefits, with the first launch focused on glucose management.

“After years of cutting-edge research into the collagen molecule, Rousselot is proud to launch Nextida, offering new health benefits beyond those traditionally attributed to collagen peptides. Nextida’s strength and innovation is to act where it matters,” said Jeroen Colpaert, executive vice president at Rousselot.

Nextida.GC (glucose control) will be the first commercialized specific collagen peptide from the Nextida platform, aiming to reduce the post-meal sugar spike in a natural way in healthy individuals.

Gaëtan Noiret, global director for health and nutrition, noted the trend for glucose metabolism and controlling blood sugar spikes has been growing of late.

“We see a lot of solutions on the market at the moment but none using collagen peptides,” Noiret told NutraIngredients.

Scientific studies revealing the impact of Nextida.GC on glucose metabolism will be unveiled at SupplySide West in Las Vegas in October 2024.

"We will disclose the mechanism of action during Supply Side West," Noiret said. "What I can say is in technical studies we see GLP-1 [glucagon-like peptide 1] plays a major role."

Speaking about Rousselot’s collagen Peptan line, he added that these provide a wide range of health benefits including sleep support and gut health as well as the expected benefits for skin and joint health, providing holistic health solutions.

Metabolic syndrome: 'the next major pandemic'

Providing a presentation on the topic of metabolic syndrome at the Vitafoods symposium, Rick Miller, associate director of specialized nutrition at Mintel, said, "We need to liken metabolic syndrome to the next major pandemic."

The main components of metabolic syndrome include obesity, high blood pressure, high blood triglycerides, low levels of HDL cholesterol and insulin resistance (glucose control).

The American Heart Association revealed one third of U.S. residents (34%) might be suffering from a level of metabolic dysfunction, Miller explained.

"The Harvard T.H. Chan School of Public Health says that in the case of diabetes, it could be prevented just by lifestyle intervention; so we're talking about diet, exercise, maybe sleep," he said.

"Continuous monitoring of glucose levels, traditionally associated with diabetes management, is expanding beyond medical contexts, although their accuracy compared to medical-grade devices is debated. Nevertheless, they offer valuable insights for consumers."